BIOMAT Database Logo BIOMAT Database Logo

Evaluation of a new immunoassay for therapeutic drug monitoring of tacrolimus in adult liver transplant recipients. 2010

Shigeru Marubashi, and Hiroaki Nagano, and Shogo Kobayashi, and Hidetoshi Eguchi, and Yutaka Takeda, and Masahiro Tanemura, and Koji Umeshita, and Morito Monden, and Yuichiro Doki, and Masaki Mori
Department of Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan. smarubashi@gesurg.med.osaka-u.ac.jp

Therapeutic drug monitoring is necessary when using tacrolimus (FK) due to the associated side effects. The aim of this study was to compare the chemiluminescent assay (CMIA) system with the previously established Abbott IMx Tacrolimus II microparticle enzyme immunoassay (MEIA) in liver transplant recipients and evaluate its accuracy. Between March and June 2008, all blood samples from the liver transplant recipients at the hospital were tested for FK trough level using 2 different methods, CMIA and MEIA. The posttransplant time, hematocrit, and other clinical parameters during the study period were recorded. FK trough level was analyzed in 398 samples from 57 liver transplant recipients by CMIA and MEIA. The correlation in FK level between the 2 methods was excellent (r(2) = 0.941). However, the FK level was underestimated in MEIA by more than 23% in samples with an FK level of less than 3.5 ng/mL and by 6.8% in those with an FK level between 3.5 and 5 ng/mL. CMIA is superior to MEIA in measuring low FK level, allowing the FK level to be maintained at less than 5 ng/mL in selected liver transplant recipients. The effects of maintaining low levels of FK should be evaluated in liver transplant recipients.

UI MeSH Term Description Entries
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008163 Luminescent Measurements Techniques used for determining the values of photometric parameters of light resulting from LUMINESCENCE. Bioluminescence Measurements,Bioluminescent Assays,Bioluminescent Measurements,Chemiluminescence Measurements,Chemiluminescent Assays,Chemiluminescent Measurements,Chemoluminescence Measurements,Luminescence Measurements,Luminescent Assays,Luminescent Techniques,Phosphorescence Measurements,Phosphorescent Assays,Phosphorescent Measurements,Assay, Bioluminescent,Assay, Chemiluminescent,Assay, Luminescent,Assay, Phosphorescent,Assays, Bioluminescent,Assays, Chemiluminescent,Assays, Luminescent,Assays, Phosphorescent,Bioluminescence Measurement,Bioluminescent Assay,Bioluminescent Measurement,Chemiluminescence Measurement,Chemiluminescent Assay,Chemiluminescent Measurement,Chemoluminescence Measurement,Luminescence Measurement,Luminescent Assay,Luminescent Measurement,Luminescent Technique,Measurement, Bioluminescence,Measurement, Bioluminescent,Measurement, Chemiluminescence,Measurement, Chemiluminescent,Measurement, Chemoluminescence,Measurement, Luminescence,Measurement, Luminescent,Measurement, Phosphorescence,Measurement, Phosphorescent,Measurements, Bioluminescence,Measurements, Bioluminescent,Measurements, Chemiluminescence,Measurements, Chemiluminescent,Measurements, Chemoluminescence,Measurements, Luminescence,Measurements, Luminescent,Measurements, Phosphorescence,Measurements, Phosphorescent,Phosphorescence Measurement,Phosphorescent Assay,Phosphorescent Measurement,Technique, Luminescent,Techniques, Luminescent
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

Shigeru Marubashi, and Hiroaki Nagano, and Shogo Kobayashi, and Hidetoshi Eguchi, and Yutaka Takeda, and Masahiro Tanemura, and Koji Umeshita, and Morito Monden, and Yuichiro Doki, and Masaki Mori
Evaluation of a Standardized Tacrolimus Therapeutic Drug Monitoring Protocol in Stable Kidney Transplant Recipients.
September 2022, Progress in transplantation (Aliso Viejo, Calif.),
Shigeru Marubashi, and Hiroaki Nagano, and Shogo Kobayashi, and Hidetoshi Eguchi, and Yutaka Takeda, and Masahiro Tanemura, and Koji Umeshita, and Morito Monden, and Yuichiro Doki, and Masaki Mori
Sampling times for monitoring tacrolimus in stable adult liver transplant recipients.
December 2004, Therapeutic drug monitoring,
Shigeru Marubashi, and Hiroaki Nagano, and Shogo Kobayashi, and Hidetoshi Eguchi, and Yutaka Takeda, and Masahiro Tanemura, and Koji Umeshita, and Morito Monden, and Yuichiro Doki, and Masaki Mori
Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients.
April 2001, Pediatric transplantation,
Shigeru Marubashi, and Hiroaki Nagano, and Shogo Kobayashi, and Hidetoshi Eguchi, and Yutaka Takeda, and Masahiro Tanemura, and Koji Umeshita, and Morito Monden, and Yuichiro Doki, and Masaki Mori
Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
October 2004, Transplantation proceedings,
Shigeru Marubashi, and Hiroaki Nagano, and Shogo Kobayashi, and Hidetoshi Eguchi, and Yutaka Takeda, and Masahiro Tanemura, and Koji Umeshita, and Morito Monden, and Yuichiro Doki, and Masaki Mori
Pharmacokinetic Model Based on Stochastic Simulation and Estimation for Therapeutic Drug Monitoring of Tacrolimus in Korean Adult Transplant Recipients.
December 2022, Therapeutic drug monitoring,
Shigeru Marubashi, and Hiroaki Nagano, and Shogo Kobayashi, and Hidetoshi Eguchi, and Yutaka Takeda, and Masahiro Tanemura, and Koji Umeshita, and Morito Monden, and Yuichiro Doki, and Masaki Mori
Tacrolimus and cardiotoxicity in adult liver transplant recipients.
August 1995, Lancet (London, England),
Shigeru Marubashi, and Hiroaki Nagano, and Shogo Kobayashi, and Hidetoshi Eguchi, and Yutaka Takeda, and Masahiro Tanemura, and Koji Umeshita, and Morito Monden, and Yuichiro Doki, and Masaki Mori
Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods.
January 2006, Transplantation proceedings,
Shigeru Marubashi, and Hiroaki Nagano, and Shogo Kobayashi, and Hidetoshi Eguchi, and Yutaka Takeda, and Masahiro Tanemura, and Koji Umeshita, and Morito Monden, and Yuichiro Doki, and Masaki Mori
Pharmacokinetic Model Based on Stochastic Simulation and Estimation for Therapeutic Drug Monitoring of Tacrolimus in Korean Adult Transplant Recipients: Erratum.
April 2023, Therapeutic drug monitoring,
Shigeru Marubashi, and Hiroaki Nagano, and Shogo Kobayashi, and Hidetoshi Eguchi, and Yutaka Takeda, and Masahiro Tanemura, and Koji Umeshita, and Morito Monden, and Yuichiro Doki, and Masaki Mori
Tacrolimus therapeutic drug monitoring in Tunisian renal transplant recipients: effect of post-transplantation period.
June 2013, Transplant immunology,
Shigeru Marubashi, and Hiroaki Nagano, and Shogo Kobayashi, and Hidetoshi Eguchi, and Yutaka Takeda, and Masahiro Tanemura, and Koji Umeshita, and Morito Monden, and Yuichiro Doki, and Masaki Mori
Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring.
August 2010, Bone marrow transplantation,
Copied contents to your clipboard!